AbCellera Biologics (Nasdaq: ABCL) announced it will present Phase 2 data on its investigational drug ABCL635 at the International Menopause ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE